Preferred Label : Allogeneic TCR-CD3 complex/CD16/IL-15-expressing Natural Killer Cells;
NCIt synonyms : Allogeneic TCR-CD3 complex/CD16/IL-15-expressing NK Cells; AD-PluReceptor-NK Cells; AD-PluReceptor NK Cells;
NCIt definition : A preparation of allogeneic natural killer (NK) cells that have been engineered to
express a T-cell receptor (TCR)-CD3 complex, CD16 Fc receptor, and interleukin 15
(IL-15), with potential immunostimulating and antineoplastic activities. Upon administration,
allogeneic TCR-CD3 complex/CD16/IL-15-expressing NK cells lyse tumor cells. Upon coadministration
with tumor-targeting and CD3-targeting bispecific antibodies, the tumor-targeting
moiety binds to the tumor-associated antigens (TAAs) expressed on tumor cells and
the anti-CD3 moiety binds to the TCR-CD3 complex expressed on the allogeneic NK cells.
This may enhance NK cell-mediated lysis of the TAA-expressing tumor cells. Upon coadministration
with certain tumor-targeting monoclonal antibodies, the Fab moiety of the antibodies
binds to the TAAs expressed on tumor cells and the Fc moiety of the antibodies binds
to CD16 expressed on the allogeneic NK cells. This leads to antibody-dependent cellular
cytotoxicity (ADCC) of the antibody-bound tumor cells. CD16, also known as Fc-gamma
receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes
and macrophages, and plays a key role in initiating ADCC. It is often downregulated
in certain cancers, thereby inhibiting the anti-tumor immune response. IL-15 promotes
the survival of NK cells and enhances the cytotoxic effect of NK cells and activated
anti-tumor T-cells.;
NCI Metathesaurus CUI : CL1928837;
Origin ID : C206683;
concept_is_in_subset
